Recent studies have centered on the overlap of GLP|GIP|glucagon receptor stimulant therapies and DA neurotransmission. While GLP agonists are commonly employed for addressing type 2 diabetes, their unexpected consequences on reinforcement circuits, specifically influenced by DA networks, are gain